secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2023-10-06T23:59:59+00:00
Accession:  0001437749-23-027863
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin Biotech shareholders approve reverse stock split authorization at special meeting
--------------------------------------------------------------------------------

- Reverse split proposal approved: 9,796,443 For, 6,858,043 Against, 170,202 Abstain.
- Board authorized to choose ratio between 1-for-5 and 1-for-20 within one year.
- Adjournment proposal also approved: 10,036,330 For, 6,686,830 Against, 101,528 Abstain.
- Board has not yet decided whether to implement a reverse split as of filing date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923027863/0001437749-23-027863-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774923027863/mbrx20231003_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-027863

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer